BACKGROUND: Ethanol (EtOH) inhibits Notch-mediated vascular smooth muscle cell (SMC) proliferation, an event that is key in vessel remodeling and atherogenesis. The object of this study was to determine whether EtOH inhibits Notch signaling in SMC at the level of γ-secretase, a protease that in concert with α-secretase catalyzes the release of the intracellular domain of the Notch receptor necessary for signaling. METHODS: Human coronary artery SMCs (HCASMCs) were treated with a recombinant soluble Notch ligand, Delta-like ligand 4 (DLL4) (2 μg/ml), or transfected with a constitutively active Notch 1 intracellular domain (N1ICD), in the absence or presence of EtOH. EtOH (25 mM) treatment inhibited DLL4-stimulated CBF-1/RBP-Jk-dependent promoter activity (determined by luciferase assay) and downstream target gene HRT-3 mRNA levels. In contrast, EtOH had no effect on N1ICD-driven CBF-1/RBP-Jk-dependent promoter activity or HRT-3 expression. RESULTS: These data suggest that EtOH inhibits Notch signaling at, or prior to, Notch intracellular domain (NICD) generation. γ-Secretase activity was determined in solubilized membrane preparations from HCASMC treated with/without EtOH (25 mM) or the γ-secretase inhibitor DAPT (20 μM) using (i) a fluorometric assay and (ii) Western blot detection of cleavage products using a Flag-tagged Notch-based substrate, N100Flag. EtOH inhibited basal and DLL4-stimulated γ-secretase activity, and SMC growth to a similar extent as DAPT, whereas it had no effect on α-secretase (TACE/ADAM17) activity also determined by fluorometric assay. Moreover, EtOH treatment inhibited the expression of caveolin-1, a lipid raft protein implicated in regulating γ-secretase activity, and altered its cellular distribution in HCASMC. CONCLUSIONS: EtOH inhibits Notch signaling in vascular SMCs at the level of γ-secretase activity, possibly by affecting lipid raft function. Such a response might be expected to result in attenuation of pathologic vessel remodeling and thus may contribute to moderate alcohols' cardioprotective effects.
BACKGROUND:Ethanol (EtOH) inhibits Notch-mediated vascular smooth muscle cell (SMC) proliferation, an event that is key in vessel remodeling and atherogenesis. The object of this study was to determine whether EtOH inhibits Notch signaling in SMC at the level of γ-secretase, a protease that in concert with α-secretase catalyzes the release of the intracellular domain of the Notch receptor necessary for signaling. METHODS:Human coronary artery SMCs (HCASMCs) were treated with a recombinant soluble Notch ligand, Delta-like ligand 4 (DLL4) (2 μg/ml), or transfected with a constitutively active Notch 1 intracellular domain (N1ICD), in the absence or presence of EtOH. EtOH (25 mM) treatment inhibited DLL4-stimulated CBF-1/RBP-Jk-dependent promoter activity (determined by luciferase assay) and downstream target gene HRT-3 mRNA levels. In contrast, EtOH had no effect on N1ICD-driven CBF-1/RBP-Jk-dependent promoter activity or HRT-3 expression. RESULTS: These data suggest that EtOH inhibits Notch signaling at, or prior to, Notch intracellular domain (NICD) generation. γ-Secretase activity was determined in solubilized membrane preparations from HCASMC treated with/without EtOH (25 mM) or the γ-secretase inhibitor DAPT (20 μM) using (i) a fluorometric assay and (ii) Western blot detection of cleavage products using a Flag-tagged Notch-based substrate, N100Flag. EtOH inhibited basal and DLL4-stimulated γ-secretase activity, and SMC growth to a similar extent as DAPT, whereas it had no effect on α-secretase (TACE/ADAM17) activity also determined by fluorometric assay. Moreover, EtOH treatment inhibited the expression of caveolin-1, a lipid raft protein implicated in regulating γ-secretase activity, and altered its cellular distribution in HCASMC. CONCLUSIONS:EtOH inhibits Notch signaling in vascular SMCs at the level of γ-secretase activity, possibly by affecting lipid raft function. Such a response might be expected to result in attenuation of pathologic vessel remodeling and thus may contribute to moderate alcohols' cardioprotective effects.
Authors: Stephanos Pavlides; Jorge L Gutierrez-Pajares; Christiane Danilo; Michael P Lisanti; Philippe G Frank Journal: Adv Exp Med Biol Date: 2012 Impact factor: 2.622
Authors: Catherine Sweeney; David Morrow; Yvonne A Birney; Seamus Coyle; Colm Hennessy; Agnieszka Scheller; Philip M Cummins; Dermot Walls; Eileen M Redmond; Paul A Cahill Journal: FASEB J Date: 2004-07-09 Impact factor: 5.191
Authors: Yuxin Li; Kyosuke Takeshita; Ping-Yen Liu; Minoru Satoh; Naotsugu Oyama; Yasushi Mukai; Michael T Chin; Luke Krebs; Michael I Kotlikoff; Freddy Radtke; Thomas Gridley; James K Liao Journal: Circulation Date: 2009-05-11 Impact factor: 29.690
Authors: Eileen M Redmond; Weimin Liu; Katie Hamm; Ekaterina Hatch; Paul A Cahill; David Morrow Journal: PLoS One Date: 2014-01-08 Impact factor: 3.240
Authors: Alaina M Reagan; Xiaowu Gu; Sijalu Paudel; Nicole M Ashpole; Michelle Zalles; William E Sonntag; Zoltan Ungvari; Anna Csiszar; Laura Otalora; Willard M Freeman; Michael B Stout; Michael H Elliott Journal: Neurobiol Aging Date: 2018-07-10 Impact factor: 4.673
Authors: Ekaterina Hatch; David Morrow; Weimin Liu; Paul A Cahill; Eileen M Redmond Journal: Am J Physiol Heart Circ Physiol Date: 2017-12-08 Impact factor: 4.733
Authors: Naresh K Rajendran; Weimin Liu; Charles C Chu; Paul A Cahill; Eileen M Redmond Journal: Alcohol Clin Exp Res Date: 2021-09-29 Impact factor: 3.455